 Potential to become the new standard of care for eschar removal in patients with deep partial- andor full- thickness thermal burns Label supported by robust clinical data demonstrating significantly higher incidence of complete eschar removal in patients treated with NexoBrid compared to placebo CAMBRIDGE, Mass., Dec. 29, 2022 GLOBE NEWSWIRE Vericel Corporation NASDAQ:VCEL, a ... The post Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults appea... 